TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$144 Million

Syndax Pharmaceuticals

Follow-on Offering

Bookrunner, December 2020

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.